Key result
Nadroparin boosts 12-month venous ulcer healing by ~23 percentage points over basic treatment alone.
RCT (n=284)
randomised
Venous ulcers are common, especially in the elderly, accounting for more than 50% of all lower extremity ulcers with important socioeconomic problems. Improving extracellular matrix functioning, by heparin administration, seems to be a way to support wound healing. A total of 284 patients with venous ulcers were recruited in a 4-year period. All patients were subjected to the most appropriate treatment after considering their preference (compression therapy followed or not by vein surgery). Patients were randomised into two groups of 142 persons in each (group A and group B as cases and controls, respectively). Patients of group A, in addition to the basic treatment as described earlier, received administration of nadroparin 2850 IU/0.3 ml through subcutaneous injection once a day for 12 months, whereas group B patients received basic treatment alone. Healing was assessed by means of direct ulcer tracing with computerised planimetry. Group A showed a healing rate of 83·80% at 12 months, whereas that of group B was 60·56%. Results by age group surprisingly showed that the group of older patients took the most advantage from long-term treatment with low molecular weight heparin; this group also had lowest recurrence rate.
No takes yet. Share an insight, caveat, or question.
Serra et al. (2013) conducted an RCT in venous ulcers (n=284). Nadroparin vs. Basic treatment alone was evaluated on Healing assessed by direct ulcer tracing with computerised planimetry at 12 months. Daily subcutaneous nadroparin added to basic treatment improved the 12-month healing rate of venous ulcers compared to basic treatment alone (83.80% vs 60.56%), particularly in older patients.
Synapse has enriched 5 related papers. Consider them for comparative context: